The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.
Yasunori Emi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Masaru Morita
No relevant relationships to disclose
Tetsuya Kusumoto
No relevant relationships to disclose
Hiroshi Matsuura
No relevant relationships to disclose
Mototsugu Shimokawa
No relevant relationships to disclose
Yoshihiro Kakeji
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Taiho Pharmaceutical